EP
EOLS icon

Eversept Partners’s Evolus EOLS Stock Holding History

Eversept Partners’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-344,104
Closed -$2.29M – 133
2025
Q4 		$2.29M Sell
344,104
-1,131,005
-77% -$7.66M 0.12% 84
2025
Q3 		$9.06M Buy
1,475,109
+304,798
+26% +$2.38M 0.62% 38
2025
Q2 		$10.8M Buy
+1,170,311
New +$12M 0.99% 30
2025
Q1 		– Sell
-383,045
Closed -$4.23M – 63
2024
Q4 		$4.23M Sell
383,045
-70,016
-15% -$985K 0.38% 45
2024
Q3 		$7.34M Sell
453,061
-121,401
-21% -$1.7M 0.5% 32
2024
Q2 		$6.23M Buy
+574,462
New +$7.07M 0.43% 40
2023
Q3 		– Sell
-228,679
Closed -$1.66M – 71
2023
Q2 		$1.66M Buy
228,679
+7,128
+3% +$61.5K 0.14% 59
2023
Q1 		$1.87M Sell
221,551
-492,223
-69% -$4.45M 0.13% 51
2022
Q4 		$5.36M Buy
+713,774
New +$5.53M 0.47% 39

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's EOLS Position: Q1 2026 in Review

Eversept Partners sold out of Evolus (EOLS) in Q1 2026, closing a stake of 344,104 shares — an estimated $2.29M sold.

Eversept Partners first reported a position in EOLS in Q4 2022 and held it in 9 quarters. The position peaked at $10.8M in Q2 2025. 147 funds tracked by Wall St. Rank hold EOLS as of Q1 2026.

  • Eversept Partners reported no remaining Evolus position as of Q1 2026 after selling out during the quarter.
  • Eversept Partners sold 344,104 Evolus shares in Q1 2026, an estimated $2.29M.
  • Eversept Partners first reported a position in Evolus in Q4 2022 and held it in 9 quarters.
  • Eversept Partners's Evolus position peaked at $10.8M in Q2 2025.
  • 147 funds tracked by Wall St. Rank held Evolus as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.